- Oral presentation
- Open Access
7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis
Pediatric Rheumatology volume 6, Article number: S15 (2008)
Etanercept has approval for use in children with polyarticular juvenile rheumatoid arthritis (JRA). Here we evaluate the safety of etanercept in children with polyarticular or systemic JRA.
This 3-year, open-label, non-randomized registry included patients age 2–18, with a diagnosis of polyarticular or systemic JRA. Patients treated with methotrexate (MTX), etanercept (ETN), or methotrexate/etanercept in combination (MTX/ETN) were eligible. Co-administration of non-biologic DMARDs was allowed. MTX was administered at 0.3 to 1 mg/kg/wk and etanercept was administered at 0.4 mg/kg (max 25 mg) twice weekly or 0.8 mg/kg (max 50 mg) weekly.
602 patients enrolled; 198 received MTX, 105 received ETN, and 299 received MTX/ETN. A total of 33%, 31%, and 35% of patients have completed the 3-year registry for a total of 388, 210, and 610 subject-years of exposure for the MTX, ETN, and MTX/ETN groups, respectively. In the MTX, ETN, and MTX/ETN groups, 18%, 8%, and 19% discontinued due to insufficient therapeutic effect while 2%, 2%, and 0.3% discontinued due to adverse events. The rates of serious adverse events and medically important infections per 100 patient-years were 4.4, 7.6, 5.7 and 1.3, 1.9, and 2.1 for patients receiving MTX, ETN, or MTX/ETN. One case of lupus (MTX) and 2 cases of sepsis (ETN and MTX/ETN) were reported. No cases of lymphoma, malignancy, tuberculosis, or death were reported.
These data suggest etanercept is safe as a long-term, continuous therapy for treatment of JRA.
Funded by Immunex, a wholly-owned subsidiary of Amgen Inc., and by Wyeth Pharmaceutical.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Giannini, E., Ilowite, N., Lovell, D. et al. 7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis. Pediatr Rheumatol 6 (Suppl 1), S15 (2008). https://doi.org/10.1186/1546-0096-6-S1-S15
- Rheumatoid Arthritis
- Therapeutic Effect